OVID Quote, Financials, Valuation and Earnings

Cidara Therapeutics, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of -30201.66%. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Cidara Therapeutics, Inc.'s return on equity of -68.74%.

Ovid Therapeutics, Inc. has a consensus price target of $4.19, signalling upside risk potential of 164.95%. On the other hand Cidara Therapeutics, Inc. has an analysts' consensus of $221.50 which suggests that it could grow by 0.24%. Given that Ovid Therapeutics, Inc. has higher upside potential than Cidara Therapeutics, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Cidara Therapeutics, Inc..

Ovid Therapeutics, Inc. has a beta of 0.045, which suggesting that the stock is 95.453% less volatile than S&P 500. In comparison Cidara Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.073%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cidara Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Cidara Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are larger than Cidara Therapeutics, Inc. quarterly revenues of --. Ovid Therapeutics, Inc.'s net income of -$12.2M is higher than Cidara Therapeutics, Inc.'s net income of -$83.2M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Cidara Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 16.99x versus 55.23x for Cidara Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of -82.06%. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Ovid Therapeutics, Inc. has a consensus price target of $4.19, signalling upside risk potential of 164.95%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.43%. Given that Ovid Therapeutics, Inc. has higher upside potential than Ionis Pharmaceuticals, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Ionis Pharmaceuticals, Inc..

Ovid Therapeutics, Inc. has a beta of 0.045, which suggesting that the stock is 95.453% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Ovid Therapeutics, Inc.'s net income of -$12.2M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 16.99x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

MannKind Corp. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of 9.72%. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat MannKind Corp.'s return on equity of --.

Ovid Therapeutics, Inc. has a consensus price target of $4.19, signalling upside risk potential of 164.95%. On the other hand MannKind Corp. has an analysts' consensus of $9.39 which suggests that it could grow by 67.96%. Given that Ovid Therapeutics, Inc. has higher upside potential than MannKind Corp., analysts believe Ovid Therapeutics, Inc. is more attractive than MannKind Corp..

Ovid Therapeutics, Inc. has a beta of 0.045, which suggesting that the stock is 95.453% less volatile than S&P 500. In comparison MannKind Corp. has a beta of 0.821, suggesting its less volatile than the S&P 500 by 17.928%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. MannKind Corp. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are smaller than MannKind Corp. quarterly revenues of $82.1M. Ovid Therapeutics, Inc.'s net income of -$12.2M is lower than MannKind Corp.'s net income of $8M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while MannKind Corp.'s PE ratio is 59.34x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 16.99x versus 5.50x for MannKind Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences, Inc. has a net margin of -9210.61% compared to Ovid Therapeutics, Inc.'s net margin of --. Ovid Therapeutics, Inc.'s return on equity of -59.7% beat Cassava Sciences, Inc.'s return on equity of -86.98%.

Ovid Therapeutics, Inc. has a consensus price target of $4.19, signalling upside risk potential of 164.95%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 158.07%. Given that Ovid Therapeutics, Inc. has higher upside potential than Cassava Sciences, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Cassava Sciences, Inc..

Ovid Therapeutics, Inc. has a beta of 0.045, which suggesting that the stock is 95.453% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.081, suggesting its less volatile than the S&P 500 by 208.123%.

Ovid Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ovid Therapeutics, Inc. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.

Ovid Therapeutics, Inc. quarterly revenues are $132K, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Ovid Therapeutics, Inc.'s net income of -$12.2M is lower than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Ovid Therapeutics, Inc.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ovid Therapeutics, Inc. is 16.99x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.